Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

BACKGROUND: Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadowski, Abbey R., Gardner, Heather L., Borgatti, Antonella, Wilson, Heather, Vail, David M., Lachowicz, Joshua, Manley, Christina, Turner, Avenelle, Klein, Mary K., Waite, Angharad, Sahora, Alexandra, London, Cheryl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109271/
https://www.ncbi.nlm.nih.gov/pubmed/30143046
http://dx.doi.org/10.1186/s12917-018-1587-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109271/
https://www.ncbi.nlm.nih.gov/pubmed/30143046
http://dx.doi.org/10.1186/s12917-018-1587-9

Ejemplares similares